Table 4 Clinical parameters associated with antisynthetase syndrome deterioration a
From: Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome
Characteristics | ASS remission/improvement | ASS deterioration | P |
|---|---|---|---|
(n = 68) | (n = 18) | ||
General characteristics | Â | Â | Â |
 Median age, years (range) | 60.5 (17 to 86) | 53 (19 to 83) | 0.002 |
 Male/female ratio | 39.7%/60.3% | 27.8%/72.2% | 0.420 |
 PM/DM subset | 61.8% PM/38.2% DM | 50% PM/50% DM | 0.424 |
 Median duration of ASS symptoms before diagnosis, months (range) | 3 (1 to 9) | 4 (1 to 13) | 0.680 |
Clinical characteristics | Â | Â | Â |
 Myalgia | 82.4% | 88.9% | 1 |
 Muscle weakness | 72% | 94.4% | 0.05 |
 Fever | 16.2% | 27.8% | 0.309 |
 Raynaud’s phenomenon | 48.5% | 50% | 1 |
 Mechanic’s hands | 29.4% | 33.3% | 0.777 |
 Joint manifestations | 66.2% | 77.8% | 0.406 |
 Esophageal involvement | 19.1% | 44.4% | 0.03 |
 Interstitial lung disease | 61.8% | 72.2% | 0.582 |
 Ventilatory insufficiency | 10.3% | 33.3% | 0.02 |
 Pyogenic pneumonia | 14.7% | 38.9% | 0.04 |
 Calcinosis cutis | 2.9% | 27.8% | 0.004 |
 Malignancy | 7.4% | 38.9% | 0.002 |